Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
4.330
+0.025 (0.58%)
At close: Feb 23, 2024, 4:00 PM
4.400
+0.070 (1.62%)
After-hours: Feb 23, 2024, 7:25 PM EST
0.58%
Market Cap 448.48M
Revenue (ttm) n/a
Net Income (ttm) -89.39M
Shares Out 103.58M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,248
Open 4.320
Previous Close 4.305
Day's Range 4.140 - 4.380
52-Week Range 1.960 - 5.600
Beta 1.40
Analysts Strong Buy
Price Target 7.75 (+78.98%)
Earnings Date Mar 22, 2024

About HUMA

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfoli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 164
Stock Exchange NASDAQ
Ticker Symbol HUMA
Full Company Profile

Financial Performance

In 2022, Humacyte's revenue was $1.57 million, an increase of 23.91% compared to the previous year's $1.26 million. Losses were -$11.97 million, -54.81% less than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price forecast is $7.75, which is an increase of 78.98% from the latest price.

Price Target
$7.75
(78.98% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine –

16 days ago - GlobeNewsWire

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

– BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine –

2 months ago - GlobeNewsWire

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commerc...

3 months ago - GlobeNewsWire

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine –

3 months ago - GlobeNewsWire

Humacyte Third Quarter 2023 Financial Results and Business Update

– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair –

3 months ago - GlobeNewsWire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commerc...

4 months ago - GlobeNewsWire

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- -Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-

4 months ago - GlobeNewsWire

Humacyte to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commer...

5 months ago - GlobeNewsWire

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commer...

5 months ago - GlobeNewsWire

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

-- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA planne...

5 months ago - GlobeNewsWire

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET

Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV ...

5 months ago - GlobeNewsWire

Results From Mayo Clinic Clinical Study of Humacyte's Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- -Researchers concluded that in the clinical study the HAV w...

5 months ago - GlobeNewsWire

Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program

-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., Aug. ...

6 months ago - GlobeNewsWire

Humacyte Second Quarter 2023 Financial Results and Business Update

– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 –

6 months ago - GlobeNewsWire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023

DURHAM, N.C., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commerci...

7 months ago - GlobeNewsWire

Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair

-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., July 26, 2023 ...

7 months ago - GlobeNewsWire

Humacyte to Present at the Jefferies Healthcare Conference

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengi...

9 months ago - GlobeNewsWire

Humacyte First Quarter 2023 Financial Results and Business Update

- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease ...

10 months ago - GlobeNewsWire

Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million

- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones,...

10 months ago - GlobeNewsWire

Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine

First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Na...

10 months ago - GlobeNewsWire

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercia...

10 months ago - GlobeNewsWire

Humacyte's Human Acellular Vessel™ (HAV™) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma

HAV granted second RMAT designation by the FDA RMAT will support Humacyte's lead indication in Vascular Trauma

10 months ago - GlobeNewsWire

Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

DURHAM, N.C., April 28, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commerc...

10 months ago - GlobeNewsWire

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally im...

10 months ago - GlobeNewsWire